Cerevance’s solengepras hits Phase 3 targets, while Australian trial shows anti-inflammatory promise

Key points

• Cerevance’s solengepras reduced average daily 'off time' by 0.61 hours versus placebo at Week 12 in the ARISE Phase 3 trial.
• The 150 mg dose also increased 'on time' by 0.60 hours and improved non-motor symptoms like daytime sleepiness.
• Cerevance plans to discuss regulatory pathways with the FDA following the successful trial results.
• An Australian-led Phase 2 trial found that SNT-4728 reduced neuroinflammation in 20 of 30 high-risk participants over 12 weeks.
• The SNT-4728 trial focused on patients with isolated rapid eye movement sleep behavior disorder, an early predictor of Parkinson’s.

Background

Parkinson’s drug development has seen mixed results recently. In April 2025, solengepras failed as a monotherapy in a Phase 2 study, missing its primary endpoint. However, the current Phase 3 success as an adjunct to levodopa marks a significant turnaround. The broader landscape includes AbbVie’s recent approval of tavapadon and Roche’s acquisition of Alector’s enzyme replacement therapy, highlighting active deal-making in the sector. Our archive notes that Cerevance had previously announced these Phase 3 results on October 8, 2026, confirming the trajectory of this development.

How outlets are covering it

Fierce Biotech and BioSpace emphasize the commercial and regulatory implications of Cerevance’s success, noting the potential for a first-in-class non-dopaminergic therapy. They highlight the contrast between the recent Phase 3 win and the earlier Phase 2 failure. The Sydney Morning Herald focuses on the preventive potential of SNT-4728, stressing the importance of targeting inflammation before significant dopamine loss occurs. While Fierce Biotech and BioSpace detail the efficacy of solengepras in treating existing symptoms, the Sydney Morning Herald highlights the earlier-stage intervention strategy of SNT-4728. The Telegraph source was inaccessible due to a security block, so no perspective could be extracted from it.

Why it matters

Solengepras offers a new mechanism for managing Parkinson’s symptoms without altering dopamine levels, potentially reducing side effects like dyskinesia associated with standard treatments. The Australian trial suggests that targeting inflammation early could slow disease progression, shifting the focus from symptom management to prevention. These developments indicate a diversification in Parkinson’s treatment strategies, moving beyond traditional dopaminergic approaches.

What to watch

Cerevance will engage with the FDA to determine the regulatory path for solengepras. Researchers behind the SNT-4721 trial plan to submit their findings to a peer-reviewed journal and conduct longer-term studies to assess sustained anti-inflammatory effects and clinical outcomes. The industry continues to explore diverse mechanisms, including stem cell therapies and other non-dopaminergic approaches.